William S Harris1, Stephen A Varvel, James V Pottala, G Russell Warnick, Joseph P McConnell. 1. Health Diagnostic Laboratory, Inc, 737 N 5th Street, Suite 103, Richmond, VA 23219, USA; OmegaQuant Analytics, LLC, Sioux Falls, SD, USA; Department of Internal Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA. Electronic address: Bharris@hdlabinc.com.
Abstract
BACKGROUND: Omega-3 fatty acid (n-3 FA) biostatus can be estimated with red blood cell (RBC) membranes or plasma. The matrix that exhibits the lower within-person variability and is less affected by an acute dose of n-3 FA is preferred in clinical practice. OBJECTIVE: We compared the acute effects of a large dose of n-3 FA on RBC and plasma levels of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). METHODS: Healthy volunteers (n = 20) were given 4 capsules containing 3.6 g of n-3 FA with a standardized breakfast. Blood samples were drawn at 0, 2, 4, 6, 8, and 24 hours. The EPA + DHA content of RBC membranes and plasma (the latter expressed as a percentage of total FA and as a concentration) were determined. General linear mixed models were used to analyze the mean response profiles in FA changes over time for plasma and RBCs. RESULTS: At 6 hours after load, the plasma concentration of EPA + DHA had increased by 47% (95% confidence interval [CI], 24% to 73%) and the plasma EPA + DHA percentage of total FA by 19% (95% CI, 4.7% to 36%). The RBC EPA + DHA percentage of composition was unchanged [-0.6% (95% CI, -2.6% to 1.5%)]. At 24 hours, the change in both of the plasma EPA + DHA markers was 10-fold greater than that in RBCs. CONCLUSIONS: An acute dose of n-3 FA (eg, a meal of oily fish or fish oil supplements) taken within a day before a doctor's visit can elevate levels of EPA + DHA in plasma, whether expressed as a percentage or a concentration, but not in RBC membranes. Similar to hemoglobin A1c, which is not affected by an acute glycemic deviation, RBCs provide a more reliable estimate of a patient's chronic EPA + DHA status than does plasma.
BACKGROUND:Omega-3 fatty acid (n-3 FA) biostatus can be estimated with red blood cell (RBC) membranes or plasma. The matrix that exhibits the lower within-person variability and is less affected by an acute dose of n-3 FA is preferred in clinical practice. OBJECTIVE: We compared the acute effects of a large dose of n-3 FA on RBC and plasma levels of eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA). METHODS: Healthy volunteers (n = 20) were given 4 capsules containing 3.6 g of n-3 FA with a standardized breakfast. Blood samples were drawn at 0, 2, 4, 6, 8, and 24 hours. The EPA +DHA content of RBC membranes and plasma (the latter expressed as a percentage of total FA and as a concentration) were determined. General linear mixed models were used to analyze the mean response profiles in FA changes over time for plasma and RBCs. RESULTS: At 6 hours after load, the plasma concentration of EPA +DHA had increased by 47% (95% confidence interval [CI], 24% to 73%) and the plasma EPA +DHA percentage of total FA by 19% (95% CI, 4.7% to 36%). The RBC EPA +DHA percentage of composition was unchanged [-0.6% (95% CI, -2.6% to 1.5%)]. At 24 hours, the change in both of the plasma EPA +DHA markers was 10-fold greater than that in RBCs. CONCLUSIONS: An acute dose of n-3 FA (eg, a meal of oily fish or fish oil supplements) taken within a day before a doctor's visit can elevate levels of EPA +DHA in plasma, whether expressed as a percentage or a concentration, but not in RBC membranes. Similar to hemoglobin A1c, which is not affected by an acute glycemic deviation, RBCs provide a more reliable estimate of a patient's chronic EPA +DHA status than does plasma.
Authors: James V Pottala; Kristine Yaffe; Jennifer G Robinson; Mark A Espeland; Robert Wallace; William S Harris Journal: Neurology Date: 2014-01-22 Impact factor: 9.910
Authors: N L Tintle; J V Pottala; S Lacey; V Ramachandran; J Westra; A Rogers; J Clark; B Olthoff; M Larson; W Harris; G C Shearer Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2014-12-02 Impact factor: 4.006
Authors: Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys Journal: Schizophr Bull Date: 2015-09-18 Impact factor: 9.306
Authors: Robert M Carney; Brian C Steinmeyer; Kenneth E Freedland; Eugene H Rubin; Michael W Rich; William S Harris Journal: J Clin Psychiatry Date: 2016-02 Impact factor: 4.384
Authors: Eric A Gurzell; Jason A Wiesinger; Christina Morkam; Sophia Hemmrich; William S Harris; Jenifer I Fenton Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2014-04-24 Impact factor: 4.006
Authors: Tiffany Thomas; Francesca Cendali; Xiaoyun Fu; Fabia Gamboni; Evan J Morrison; Jonathan Beirne; Travis Nemkov; Marianna H Antonelou; Anastasios Kriebardis; Ian Welsby; Ariel Hay; Karolina H Dziewulska; Michael P Busch; Steven Kleinman; Paul W Buehler; Steven L Spitalnik; James C Zimring; Angelo D'Alessandro Journal: Transfusion Date: 2021-04-26 Impact factor: 3.337